- Home
- ODD vs BLTE Comparison
ODD vs BLTE Comparison
Compare ODD & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODD
- BLTE
- Stock Information
- Founded
- ODD 2018
- BLTE 2018
- Country
- ODD Israel
- BLTE United States
- Employees
- ODD N/A
- BLTE N/A
- Industry
- ODD
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- ODD
- BLTE Health Care
- Exchange
- ODD Nasdaq
- BLTE Nasdaq
- Market Cap
- ODD 2.6B
- BLTE 2.1B
- IPO Year
- ODD 2023
- BLTE 2022
- Fundamental
- Price
- ODD $39.75
- BLTE $82.81
- Analyst Decision
- ODD Buy
- BLTE Strong Buy
- Analyst Count
- ODD 6
- BLTE 4
- Target Price
- ODD $53.67
- BLTE $89.00
- AVG Volume (30 Days)
- ODD 375.8K
- BLTE 110.7K
- Earning Date
- ODD 11-06-2024
- BLTE 11-12-2024
- Dividend Yield
- ODD N/A
- BLTE N/A
- EPS Growth
- ODD 80.44
- BLTE N/A
- EPS
- ODD 1.64
- BLTE N/A
- Revenue
- ODD $620,646,000.00
- BLTE N/A
- Revenue This Year
- ODD $27.40
- BLTE N/A
- Revenue Next Year
- ODD $20.03
- BLTE N/A
- P/E Ratio
- ODD $24.18
- BLTE N/A
- Revenue Growth
- ODD 29.59
- BLTE N/A
- 52 Week Low
- ODD $30.34
- BLTE $31.01
- 52 Week High
- ODD $50.36
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- ODD 45.25
- BLTE 73.39
- Support Level
- ODD $40.06
- BLTE $77.62
- Resistance Level
- ODD $47.08
- BLTE $86.53
- Average True Range (ATR)
- ODD 2.39
- BLTE 5.84
- MACD
- ODD -0.03
- BLTE 0.69
- Stochastic Oscillator
- ODD 23.33
- BLTE 88.01
About ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.